J
Jeffrey H. Wisoff
Researcher at New York University
Publications - 160
Citations - 10772
Jeffrey H. Wisoff is an academic researcher from New York University. The author has contributed to research in topics: Hydrocephalus & Craniopharyngioma. The author has an hindex of 58, co-authored 155 publications receiving 9841 citations. Previous affiliations of Jeffrey H. Wisoff include Primary Children's Hospital & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions From the Children's Cancer Group 921 Randomized Phase III Study
Paul M. Zeltzer,James M. Boyett,Jonathan L. Finlay,A. Leland Albright,L B Rorke,Jerrold M. Milstein,Jeffrey C. Allen,Kenneth R. Stevens,P Stanley,Hao Li,Jeffrey H. Wisoff,J. Russell Geyer,Patsy McGuire-Cullen,James A. Stehbens,Susan B. Shurin,Roger J. Packer +15 more
TL;DR: VCPplus XRT is a superior adjuvant combination compared with 8-in-1 chemotherapy plus XRT, and for patients with M0 tumors, residual tumor bulk (not extent of resection) is a predictor for PFS.
Journal ArticleDOI
Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group
Jonathan L. Finlay,James M. Boyett,Allan J. Yates,Jeffrey H. Wisoff,Jerrold M. Milstein,J R Geyer,Salvatore Bertolone,P McGuire,Joel M. Cherlow,M Tefft +9 more
TL;DR: There is no benefit to the treatment of high-grade astrocytomas in children with eight-drugs-in-1-day chemotherapy compared with CCNU, vincristine, and prednisone, and a difference in toxicity between the two chemotherapeutic regimens.
Journal ArticleDOI
Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group
Patricia L. Robertson,Paul M. Zeltzer,James M. Boyett,Lucy B. Rorke,Jeffrey C. Allen,J. Russell Geyer,Philip Stanley,Hao Li,A. Leland Albright,Patricia McGuire-Cullen,Jonathan L. Finlay,Kenneth R. Stevens,Jerrold M. Milstein,Roger J. Packer,Jeffrey H. Wisoff +14 more
TL;DR: The pattern of predominantly local relapse and the important influence of residual tumor or the extent of resection on PFS duration confirms a prevailing impression that local disease control is the major factor in the prediction of outcome of ependymoma.
Journal ArticleDOI
Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
Joann L. Ater,Tianni Zhou,Emiko J. Holmes,Claire Mazewski,Timothy N. Booth,David R. Freyer,Ken H. Lazarus,Roger J. Packer,Michael D. Prados,Richard Sposto,Gilbert Vezina,Jeffrey H. Wisoff,Ian F. Pollack +12 more
TL;DR: Compared two chemotherapy regimens for LGGs in children younger than age 10 years for whom radiotherapy was felt by the practitioner to pose a high risk of neurodevelopmental injury, the difference in EFS did not reach significance on the basis of the stratified log-rank test.
Journal ArticleDOI
Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome.
Howard L. Weiner,Jeffrey H. Wisoff,Michael E. Rosenberg,Mark J. Kupersmith,Henry Cohen,David Zagzag,Tania Shiminski-Maher,Eugene S. Flamm,Fred Epstein,Douglas C. Miller +9 more
TL;DR: Analysis of data from 56 patients operated on for craniopharyngioma since 1981 determined the utility of dividing patients with this tumor into distinct clinical groups based on recognized pathological type.